Company intelligence / Profile preview

Apollon Inc.

Ownership: Private
Employees: ~22
Development stage: Other

Overview

Apollon's needle-free CGM device ("MOGLU") uses miniaturized Raman spectroscopy to measure blood glucose continuously and non-invasively. Early results indicate accuracy comparable to traditional CGMs with improved comfort and cost-effectiveness. Ongoing clinical studies are being conducted in collaboration with MIT; human data release anticipated soon. The company claims the device meets FDA standards for accuracy and safety.

Therapeutic areas: Endocrinology
Modalities: Non-invasive continuous glucose monitoringRaman spectroscopy
Industry: Physiological Monitoring

Partnerships

Massachusetts Institute of Technology (MIT) – joint research & small-scale clinical trials since July 2023

Beyond the preview

Go deeper on Apollon Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apollon Inc..